167 related articles for article (PubMed ID: 14581270)
1. A trial-based cost-effectiveness analysis of letrozole followed by tamoxifen versus tamoxifen followed by letrozole for postmenopausal advanced breast cancer.
Karnon J; Johnston SR; Jones T; Glendenning A
Ann Oncol; 2003 Nov; 14(11):1629-33. PubMed ID: 14581270
[TBL] [Abstract][Full Text] [Related]
2. Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.
Dunn C; Keam SJ
Pharmacoeconomics; 2006; 24(5):495-517. PubMed ID: 16706574
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Sofrygin O; Thomas SK; Papo NL; Barghout V
Clin Breast Cancer; 2007 Jun; 7(8):608-18. PubMed ID: 17592673
[TBL] [Abstract][Full Text] [Related]
5. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
[TBL] [Abstract][Full Text] [Related]
6. A stochastic economic evaluation of letrozole versus tamoxifen as a first-line hormonal therapy: for advanced breast cancer in postmenopausal patients.
Karnon J; Jones T
Pharmacoeconomics; 2003; 21(7):513-25. PubMed ID: 12696991
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.
Delea TE; El-Ouagari K; Karnon J; Sofrygin O
Breast Cancer Res Treat; 2008 Apr; 108(3):375-87. PubMed ID: 17653859
[TBL] [Abstract][Full Text] [Related]
8. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
Marchetti M; Caruggi M; Colombo G
Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of letrozole versus tamoxifen as first-line hormonal therapy in treating postmenopausal women with advanced breast cancer in Japan.
Okubo I; Kondo M; Toi M; Ochiai T; Miki S
Gan To Kagaku Ryoho; 2005 Mar; 32(3):351-63. PubMed ID: 15791818
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
Mistry R; May JR; Suri G; Young K; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya S; Mishra D; Bhattacharyya D; Dalal AA
J Manag Care Spec Pharm; 2018 Jun; 24(6):514-523. PubMed ID: 29799329
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial.
Locker GY; Mansel R; Cella D; Dobrez D; Sorensen S; Gandhi SK;
Breast Cancer Res Treat; 2007 Dec; 106(2):229-38. PubMed ID: 17245540
[TBL] [Abstract][Full Text] [Related]
12. Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen.
Dranitsaris G; Verma S; Trudeau M
Am J Clin Oncol; 2003 Jun; 26(3):289-96. PubMed ID: 12796603
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR+ early-stage breast cancer.
Lipsitz M; Delea TE; Guo A
Curr Med Res Opin; 2010 Oct; 26(10):2315-28. PubMed ID: 20731528
[TBL] [Abstract][Full Text] [Related]
14. Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer.
Gil JM; Rubio-Terrés C; Del Castillo A; González P; Canorea F
Clin Transl Oncol; 2006 May; 8(5):339-48. PubMed ID: 16760009
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of the prevention and treatment of breast cancer--present status and open issues.
Imai H; Kuroi K; Ohsumi S; Ono M; Shimozuma K
Breast Cancer; 2007; 14(1):81-7. PubMed ID: 17245000
[TBL] [Abstract][Full Text] [Related]
16. Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective.
Karnon J; Delea T; Barghout V
Eur J Health Econ; 2008 May; 9(2):171-83. PubMed ID: 17602251
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective.
Karnon J; Delea T; Johnston SR; Smith R; Brandman J; Sung J; Goss PE
Pharmacoeconomics; 2006; 24(3):237-50. PubMed ID: 16519546
[TBL] [Abstract][Full Text] [Related]
18. Letrozole: a review of its use in postmenopausal women with breast cancer.
Simpson D; Curran MP; Perry CM
Drugs; 2004; 64(11):1213-30. PubMed ID: 15161328
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial.
Mansel R; Locker G; Fallowfield L; Benedict A; Jones D
Br J Cancer; 2007 Jul; 97(2):152-61. PubMed ID: 17622238
[TBL] [Abstract][Full Text] [Related]
20. Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole.
Skedgel C; Rayson D; Dewar R; Younis T
Breast; 2007 Jun; 16(3):252-61. PubMed ID: 17207623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
